Financial Blogger, Contributor, Model Portfolio
Bret Jensen is a financial blogger and contributor, specializing in providing analysis and insights on various stocks and investment opportunities. With a focus on the financial market, Bret's articles cover a range of topics including company analysis, market trends, and investment strategies. His work has been featured in Seeking Alpha and TheStreet.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Bret Jensen's articles predominantly cover investment analysis in the healthcare, pharmaceutical, and biotechnology sectors. He frequently cites data to support his analysis. To effectively reach out to Bret, provide well-researched insights or expert commentary on companies within the pharmaceutical and biotech industries that are backed by solid data and financial analysis.
Given his focus on stock market coverage within these sectors, pitches should be tailored to appeal to investors seeking detailed financial and industry-specific insights into pharmaceuticals, biotechnology, and medical technology companies. Although Bret doesn't have a specific geographic focus mentioned, it would be beneficial for sources with international perspectives or those impacting global markets to engage him effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Looking for Attractive Gains in the Weight Loss Space
Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom.
Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A volume in the coming year. Click here to read our picks.
By: Bret Jensen
Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH.
At current levels, the S&P 500 is providing next to no risk premium compared to risk-free assets like the 10-Year Treasury. Read more on SPY ETF here.
Stagflation Is Becoming the Baseline Economic Scenario
Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT.
All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.
We've Got You 'Covered' on This Bet on Big Pharma
Stocks Climb a Tall Wall of Worry
(833) 317-6278 
